# Complete Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/complete-genomics

- Industry: Biotechnology
- Headquarters: Mountain View, US
- Website: www.completegenomics.com
- Total disclosed funding: $104M
- Latest round: Series E (Aug 19, 2010)
- Investors on record: 8

## About

Complete Genomics is a biotechnology company specializing in next-generation sequencing solutions, focusing on spatial transcriptomics and whole genome sequencing to advance genomic research.Founded in 2005 in Mountain View, US, Complete Genomics offers genomic sequencing solutions. The company has undergone significant developments, including its acquisition by BGI in September 2012 for USD 117.60 mn. The company has completed a total of 10 deals since its inception. The founders, Keith Barkley and Robert Ragot, have been instrumental in guiding the company's vision, while Cliff Reid serves as the CEO. The latest funding round occurred in March 2012, led by Shenzhen Huada Gene Technology Co., Ltd., raising USD 3.10 mn.Complete Genomics specializes in providing advanced next-generation sequencing (NGS) solutions, emphasizing spatial transcriptomics and whole genome sequencing. Their flagship DNBSEQ™ technology utilizes rolling circle replication (RCR) for accurate, PCR-free sequencing. The product suite includes extraction and library preparation kits, and sequencing platforms, facilitating efficient workflows for applications in microbiology, plant, and animal genomics. The company serves a diverse clientele, including academic institutions and biotechnology firms worldwide, enhancing their genomic research capabilities through innovative solutions.Complete Genomics reported a revenue of USD 19.34 mn for the year 2011. The company primarily generates revenue from direct sales of its sequencing products and services to research institutions and biotechnology companies. Their offerings, particularly the DNBSEQ™ sequencing platforms, are designed for high-throughput applications, catering to various research budgets and project scales.The company aims to leverage recent funding to strengthen its position in the genomics market by expanding its product line and enhancing technological capabilities. Future product developments are expected to include new sequencing technologies targeting academic and commercial sectors by 2013. Additionally, Complete Genomics plans to expand its market presence in Europe and Asia, aiming for significant geographic diversification by late 2013. The funds raised in the latest round will support these initiatives and further investment in research and development.

## Funding rounds

- Series E, Aug 19, 2010, $39M — Enterprise Partners Venture Capital, Essex Woodlands, OrbiMed Advisors, OVP Venture Partners, Prospect Venture Partners, NexPoint Asset Management, Sands Capital Alternatives
- Series D, Aug 24, 2009, $45M — Enterprise Partners Venture Capital, Essex Woodlands, OrbiMed Advisors, OVP Venture Partners, Prospect Venture Partners, NexPoint Asset Management
- Series B, Oct 5, 2007, $1M — Prospect Venture Partners, Enterprise Equity Venture Capital
- Series B, Mar 19, 2007, $13M — Enterprise Partners Venture Capital, OVP Venture Partners, Prospect Venture Partners
- Series A, Mar 28, 2006, $6M — Enterprise Partners Venture Capital, OVP Venture Partners

## Investors

- Enterprise Partners Venture Capital (https://capitalatlas.ai/funds/enterprise-partners-venture-capital) — Series A, Series B, Series D, Series E
- OVP Venture Partners (https://capitalatlas.ai/funds/ovp-venture-partners) — Series A, Series B, Series D, Series E
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B, Series D, Series E
- Enterprise Equity Venture Capital (https://capitalatlas.ai/funds/enterprise-equity-venture-capital) — Series B
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series D, Series E
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D, Series E
- NexPoint Asset Management (https://capitalatlas.ai/funds/nexpoint-asset-management) — Series D, Series E
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series E